Larcaviximab Biosimilar – Anti-Zaire Ebola virus mAb – Research Grade from ProteoGenix; catalogue PX-TA1470; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Larcaviximab Biosimilar, also known as Anti-Zaire Ebola virus mAb, is a monoclonal antibody that has been developed as a potential treatment for Ebola virus infection. This biosimilar is a research grade version of the original Larcaviximab, which has shown promising results in pre-clinical studies and is currently undergoing clinical trials. In this article, we will discuss the structure, activity, and potential applications of Larcaviximab Biosimilar as an antibody therapeutic targeting the Ebola virus.
Larcaviximab Biosimilar is a monoclonal antibody that specifically targets the Zaire strain of the Ebola virus. It is a humanized antibody, meaning that it has been engineered to have a human-like structure, reducing the risk of immune reactions when used in patients. The antibody is composed of two identical heavy chains and two identical light chains, connected by disulfide bonds. The heavy chains contain a constant region and a variable region, while the light chains only have a variable region. The variable regions of the antibody are responsible for binding to the Ebola virus and initiating the immune response.
Larcaviximab Biosimilar works by binding to a specific protein on the surface of the Ebola virus known as the glycoprotein. This protein is essential for the virus to enter and infect human cells. By binding to the glycoprotein, Larcaviximab Biosimilar prevents the virus from entering cells, effectively neutralizing its activity. It also triggers the immune system to recognize and destroy the virus, providing a dual mechanism of action against Ebola infection.
In addition to its direct antiviral activity, Larcaviximab Biosimilar has been shown to have a long half-life in the body, allowing for sustained protection against the Ebola virus. This is important in the treatment of Ebola, as the virus can remain in the body for an extended period of time, leading to recurrent infections and a high mortality rate.
The primary application of Larcaviximab Biosimilar is in the treatment of Ebola virus infection. It has shown promising results in pre-clinical studies, demonstrating its ability to neutralize the virus and reduce mortality rates. The biosimilar is currently undergoing clinical trials to determine its safety and efficacy in humans, with the goal of obtaining regulatory approval for its use as a therapeutic agent.
In addition to its potential as a treatment for Ebola, Larcaviximab Biosimilar may also have applications in the prevention of infection. By providing passive immunity, the biosimilar could be used as a prophylactic treatment for individuals at high risk of exposure to the Ebola virus, such as healthcare workers and individuals living in areas with high rates of infection.
Furthermore, Larcaviximab Biosimilar could also have potential applications in the treatment of other viral diseases. The technology used to develop this biosimilar could be applied to other viruses, allowing for the production of similar antibodies targeting different viral strains. This could lead to the development of a broad-spectrum antiviral therapy that could be used in the treatment of emerging viral diseases.
Larcaviximab Biosimilar, also known as Anti-Zaire Ebola virus mAb, is a promising monoclonal antibody therapy for the treatment of Ebola virus infection. Its unique structure and mechanism of action make it a potential game-changer in the fight against this deadly virus. While further research is needed to fully understand its potential, Larcaviximab Biosimilar has the potential to save countless lives and provide much-needed protection against Ebola and other viral diseases.
ProteoGenix catalogue number PX-TA1470. For research use only.
Target: Larcaviximab Biosimilar – Anti-Zaire Ebola virus mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Larcaviximab Biosimilar – Anti-Zaire Ebola virus mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
